SLC5A2 and hydrops fetalis: Recently, sodium-glucose cotransporter-2 inhibitors, known to potently and rapidly reduce the risk of developing HF and HF-related events in DM [105,106,107], were reportedly shown to correct endothelial dysfunction [108,109], improve large artery compliance [108,110], prevent LV hypertrophy [109] and diastolic dysfunction [111].